Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis

by Pavel Kovalenko, Anne Paccaly, Anita Boyapati, Christine Xu, Gregory St John, Michael C. Nivens, John D. Davis, Ronda Rippley, A. Thomas DiCioccio
Published 2020-07-01

Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies

by Jacques Rey, Franck Poitiers, Tobias Paehler, Aurélie Brunet, A. Thomas DiCioccio, Christopher P. Cannon, Howard K. Surks, Jean‐Louis Pinquier, Corinne Hanotin, William J. Sasiela
Published 2016-06-01

A drug‐disease model for predicting survival in an Ebola outbreak

by Masood Khaksar Toroghi, Nidal Al‐Huniti, John D. Davis, A. Thomas DiCioccio, Ronda Rippley, Alina Baum, Christos A. Kyratsous, Sumathi Sivapalasingam, Joel Kantrowitz, Mohamed A. Kamal
Published 2022-10-01

Translational findings for odronextamab: From preclinical research to a first‐in‐human study in patients with CD20+ B‐cell malignancies

by Min Zhu, Kara Olson, Jessica R. Kirshner, Masood Khaksar Toroghi, Hong Yan, Lauric Haber, Craig Meagher, Dina M. Flink, Srikanth R. Ambati, John D. Davis, A. Thomas DiCioccio, Eric J. Smith, Marc W. Retter
Published 2022-04-01

Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies

by Rey, Jacques, Poitiers, Franck, Paehler, Tobias, Brunet, Aurélie, DiCioccio, A. Thomas, Cannon, Christopher P., Surks, Howard K., Pinquier, Jean‐Louis, Hanotin, Corinne, Sasiela, William J.
Published 2016